Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > Press > BioNanomatrix Secures $23.3 Million in Series B Financing: Domain Associates leads round for genomics company; Battelle Ventures, Gund Investment Corp., Innovation Valley Partners and KT Venture Group participate

Abstract:
BioNanomatrix, Inc., a developer of nanoscale, single-molecule imaging and analysis platforms designed to dramatically reduce the time and cost needed to analyze the genome, has closed a $23.3-million Series B round of equity financing.

BioNanomatrix Secures $23.3 Million in Series B Financing: Domain Associates leads round for genomics company; Battelle Ventures, Gund Investment Corp., Innovation Valley Partners and KT Venture Group participate

Philadelphia, PA | Posted on March 18th, 2011

Domain Associates, based in Princeton, N.J., and San Diego, Calif., led the round, with new investor Gund Investment Corporation and existing investors Battelle Ventures, Innovation Valley Partners and KT Venture Group joining the round.

"The Series B financing comes at a pivotal time for the company, as we advance toward commercialization of our unique nanoAnalyzer platform for whole genome analysis," said R. Erik Holmlin, newly elected president and chief executive officer of BioNanomatrix.

Holmlin noted that BioNanomatrix introduced the nanoAnalyzer 1000 System at the 2010 annual meeting of the American Society of Human Genetics last November and said that the company "has already placed a number of systems with early-access users."

"BioNanomatrix has made impressive progress in developing and refining its platform technology and testing the nanoAnalyzer in collaboration with leading researchers in the genomics field," said Domain Associates Partner Brian K. Halak, PhD., who joins the company's Board of Directors.

"This capital infusion enables BioNanomatrix to establish a strong West Coast presence that will provide additional business opportunities and the ability to recruit from a talent base that has established this industry," Dr. Halak continued.

"Looking ahead," he said, "we are confident that the affordability, speed and simplicity of the nanoAnalyzer technology will make the routine use of genetic information feasible in broad-ranging applications, including molecular diagnostics, personalized medicine and biomedical research."

####

About BioNanomatrix, Inc.
Named in 2010 as one of 50 companies to watch by Medical Device and Diagnostic Industry, BioNanomatrix is developing and commercializing technologies for analysis of large biological molecules, such as nucleic acids, which are vital to life science research, clinical diagnostic applications and development of new therapeutics. This technology is designed to dramatically reduce the time and complexity to analyze the genome and provide additional information, including structural variation data, which is not easily addressed with current methods. The company’s products will provide users with the means to perform single-molecule analyses on minute biological samples that are essentially unattainable, too impractical or too costly to achieve using current technology. The company’s current development efforts include a NIST-ATP-funded project to sequence the human genome at a cost of $100, as well as support from the National Institutes of Health.

Note: BioNanomatrix and nanoAnalyzer are trademarks of BioNanomatrix, Inc. Any other names of actual companies, organizations, entities, products or services may be the trademarks of their respective owners.

For more information, please click here

Contacts:
Rick Sacks
973-467-8728

Copyright © Business Wire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Bioengineered nanoparticles show promise for fibrinogen manufacture, says Journal of Pharmaceutical Analysis study: Scientists engineer a nanoparticle polymer that can selectively bind to fibrinogen in human plasma, presenting a pathway for improved drug development January 14th, 2022

Photon recycling – The key to high-efficiency perovskite solar cells January 14th, 2022

NSF funds Rice effort to measure, preserve quantum entanglement: Physicist Guido Pagano wins CAREER Award to develop tools for quantum computing January 14th, 2022

Tuning the bonds of paired quantum particles to create dissipationless flow: A tunable platform made from atomically thin materials may help researchers figure out how to create a robust quantum condensate that can flow without losing energy January 14th, 2022

Imaging

JEOL Introduces New Scanning Electron Microscope with “Simple SEM” Automation and Live Elemental and 3D Analysis January 14th, 2022

Super-resolved imaging of a single cold atom on a nanosecond timescale January 7th, 2022

Researchers use electron microscope to turn nanotube into tiny transistor December 24th, 2021

Major instrumentation initiative for research into quantum technologies: Paderborn University receives funding from German Research Foundation December 24th, 2021

VC/Funding/Angel financing/Loans/Leases/Crowdfunding

180 Degree Capital Corp. Reports +14.2% Growth in Q1 2021, $10.60 Net Asset Value Per Share as of March 31, 2021, and Developments From Q2 2021 May 11th, 2021

180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021

180 Degree Capital Corp. Reports +6.7% Growth in Q4 2020, $9.28 Net Asset Value per Share as of December 31, 2020, and Developments from Q1 2021 Including Expected Investment in a Planned SPAC Sponsor February 22nd, 2021

180 Degree Capital Corp. to Report Fourth Quarter 2020 Financial Results on Monday, February 22, 2021 and to Host a Conference Call on Tuesday, February 23, 2021 February 19th, 2021

Investments/IPO's/Splits

Daikin Industries becomes OCSiAl shareholder July 27th, 2021

180 Degree Capital Corp. Reports +14.2% Growth in Q1 2021, $10.60 Net Asset Value Per Share as of March 31, 2021, and Developments From Q2 2021 May 11th, 2021

INBRAIN Neuroelectronics raises over €14M to develop smart graphene-based neural implants for personalised therapies in brain disorders March 26th, 2021

180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021

Announcements

Nanostructures get complex with electron equivalents: Nanoparticles of two different sizes break away from symmetrical designs January 14th, 2022

New photonic effect could speed drug development: Twisted semiconductor nanostructures convert red light into the twisted blue light in tiny volumes, which may help develop chiral drugs January 14th, 2022

UT Southwestern develops nanotherapeutic to ward off liver cancer January 14th, 2022

The free-energy principle explains the brain January 14th, 2022

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project